Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.11B P/E - EPS this Y 24.90% Ern Qtrly Grth -
Income -167.48M Forward P/E -5.49 EPS next Y -1.70% 50D Avg Chg 2.00%
Sales 8.19M PEG - EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 3.13 EPS next 5Y - 52W High Chg -55.00%
Recommedations 1.90 Quick Ratio 3.96 Shares Outstanding 98.31M 52W Low Chg 18.00%
Insider Own 19.60% ROA -42.22% Shares Float 60.10M Beta -1.52
Inst Own 87.02% ROE -45.71% Shares Shorted/Prior 15.10M/13.57M Price 12.80
Gross Margin 91.37% Profit Margin - Avg. Volume 1,224,093 Target Price 39.25
Oper. Margin -1,401.45% Earnings Date - Volume 994,626 Change -4.12%
About Day One Biopharmaceuticals, Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals, Inc News
12/17/24 Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16/24 How Trump Can Help Crypto on Day One
12/06/24 Instagram locks out developers of third-party consumer apps
11/27/24 Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?
11/20/24 Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
11/18/24 Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/06/24 Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
11/06/24 Exploring Three High Growth Tech Stocks in the United States
11/04/24 Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts
11/01/24 We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
10/30/24 Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates
10/30/24 Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
08:55 AM Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet
10/16/24 Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma
10/16/24 Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
10/01/24 At What Oil Price Will Shale Drillers Stop Drilling?
08/19/24 Jeff Bezos Said 'I Predict One Day Amazon Will Fail' And Claims Large Companies Only Last '30-Plus Years' – Guess How Old Amazon Is?
08/16/24 A great week that adds to Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) one-year returns, institutional investors who own 56% must be happy
08/14/24 Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
08/07/24 Dow Jones Futures Fuel New Market Rally On Bank Of Japan; Nvidia Partner Super Micro Dives
DAWN Chatroom

User Image TomatoeKetchup Posted - 1 day ago

$DAWN give me $10.00 🪨🍅

User Image TomatoeKetchup Posted - 1 day ago

$DAWN scam! 🛑🍅

User Image Smatty Posted - 2 days ago

$DAWN If it hangs out this low I'd be shocked if it isnt acquired. IIP plus all that cash...

User Image Slapshot22 Posted - 3 days ago

$ARDX $CAPR $IOVA $DAWN $VKTX Not sure how @BloodandSun finds the time to hate every stock he/she/they post on. We get it, you hate them all. No value added. Blocked.

User Image classicequity Posted - 3 days ago

$DAWN commercial biotech with strong balance sheet and growth, currently a strong value due to its weight in $XBI dragging it down on low volume. Firefly 2 study can have this in the 20's in a flash

User Image MoneyWise13 Posted - 4 days ago

$DAWN Zoom out to the all-time chart and you'll see this is coiled so tight in the $10-$15 range. Only a matter of time

User Image MoneyWise13 Posted - 4 days ago

$DAWN

User Image MoneyWise13 Posted - 5 days ago

$DAWN This is a classic BP play. Have MMs walk this down then take them out. No reason this should be trading at these levels

User Image Night_Owl_Biotech Posted - 1 week ago

Attached is a table of all 16 commercial-stage oncology focused bios noting their closing share price today v. 2 weeks ago. $DCTH is the only bio in this peer group trading higher (with a lower FY28 revenue multiple). $IOVA & $SWTX now trade for less than 2.0X FY28 analyst consensus revenue estimates (year 4). SWTX has noted it has enough cash to get to breakeven. IOVA's CEO noted 3 weeks ago that IOVA has a pathway to profitability "without the need for significant additional capital." Recall Centerview Partners, in its MRTX fairness opinion, noted the median Year 4 revenue multiple paid of 8 MRTX peers M&A transactions was 6.0X. Decide for yourself if SWTX & IOVA are MRTX peers. SWTX owes Pfizer royalties of up to 20% on sales. IOVA forecasts 70% gross margins which may adversely affect multiple comps $URGN & $DAWN trade @ discounts to recent financings (URGN at $17.50 in 6/24 & DAWN at $14.50 in 7/24). For information only. This is not investment advice.

User Image Paddy444 Posted - 1 week ago

$DAWN Markets are so good for finding value early, it's my forte. It's how I lasted so long in this profession. The market lags on strong substance and thrives on quick scams. I trade the scams for fun and excess capital while the real money is made on early value opportunities like $DAWN and $ALGS I mention ALGS because it was 18.00 and will cross 40.00 soon and it so nice and quiet.

User Image Paddy444 Posted - 1 week ago

@killbilltrader Markets are so good for finding value early, it's my forte. It's how I lasted so long in this profession. The market lags on strong substance and thrives on quick scams. I trade the scams for fun and excess capital while the real money is made on early value opportunities like $DAWN and $ALGS I mention ALGS because it was 18.00 and will cross 40.00 soon and it so nice and quiet. Like here

User Image killbilltrader Posted - 1 week ago

$DAWN They have 560M cash that is 50% of the MC and an FDA approved cancer product with >1B rev potential on the market. But the stock is trading like a pre-clinical Bio. The stock pattern looks similar to $PRVB. Hope BP buys this out for. 200-300% premium soon.

User Image MoneyWise13 Posted - 1 week ago

$DAWN The big guys are grabbing up all the shares here for a 1H25 BO. It's pretty incredible to watch. Great sales figures after first quarter of sales for only therapeutic treatment available. Retail not paying attention at all and that's how the HFs like it

User Image Paddy444 Posted - 1 week ago

$DAWN My forte is finding value early that also has strong aspects to actually match the cap to the hard work that's in the pipeline. It's nice a quiet here, very good sign for continued accumulation. I really see a solid opportunity here How can anyone really expect consistent and relaxed patience to let the investments grow if not heavily diversified? When diversified, there is always something good going on. Makes decision making way easier. No big deal 27 plus years, I do know what works

User Image Doozio Posted - 1 week ago

$DAWN bahhht…. Only da dingleberries remain!!! 🐑👀

User Image Rollercoaster22 Posted - 1 week ago

$DAWN How is this even possible? 🤣

User Image HoHoHoHum Posted - 1 week ago

$DAWN new to this. what is the potential bo price for this?

User Image Dr_Van_Nostrend Posted - 1 week ago

$DAWN Going to perform some valuation math here. Value is growing at a very good clip. Company says growth in Ojemda scripts is very strong and consistent. 1700 cases of PLGG are diagnosed every year in the US. They are growing by about 120 patients per qtr, 40 patients per month. Currently about 200 patients on drug which led to the 600 scripts in Q3. 40 patients per month, X 12 = 480 patients a year adoption rates on new scripts. Doesn't include already diagnosed patients getting on to drug either. That's a nice starting penetration rate. At current clip... 480 patients added per year means 480 x 12 script run rate , one script per month per patient = 5760 scripts run rate per year CURRENTLY. 5760 x 33500 revenue per script = $192,960,000 revenue run rate on steady growth. Biotechs avg 6.44 price to sales ratios... $192,960,000 x 6.44. = $1,242,662,400. Add in their cash of 550M and discounting the rest of their pipeline to zero, you get 1,792,662,400 MC or 17.77 pps

User Image Night_Owl_Biotech Posted - 1 week ago

Attached on left: all comm'l-stage oncology focused M&A since FY13 sorted by months v FDA appr. It appears most successful M&A (for investors) in this peer group was within 24 months of a major FDA approval. MDVN was an outlier (there were very few peers at the time). To the right: all active peers with a market cap < $7.5B noting # of months since approval (from yesterday's post plus FY28 revenue multiples) Guess of M&A by 12/31/25 $DAWN Ojemda's patent expires in FY35? (c/b wrong) $SWTX It is hard to see how SWTX's outlook gets any better perhaps excl Ogsiveo's P2 OvGCT data in 1H25 $IOVA Speaks for itself. If analysts & IOVA are right then TIL is at the "tip of the iceberg" for enormous growth $URGN Off 30% since 6/24 raise @ $17.50/share subject to same patent risks $ZYME Jazz predicts $2B in Ziihera sales (tiered royalties "10-20%") For entertainment purposes only. This is not investment advice. We have no idea if there will be any M&A

User Image Paddy444 Posted - 1 week ago

$DAWN Europ trip, 2 million, early value is here if you want to see it. Or not Market norms and funny Later

User Image Paddy444 Posted - 1 week ago

$DAWN 2 million. Instincts or Morning wine could be it Prost

User Image lolo14 Posted - 2 weeks ago

@YazzJr What "fire chat for few hours"? The same conference $DAWN posted 30 min of the story we already know. It would be the same with AQST. 30 min non event. If what they say as"scheduling issue" have something to do with BO , I don't mind .

User Image tedevan Posted - 2 weeks ago

$BPMC $MRUS $IOVA $SWTX $DAWN

User Image Night_Owl_Biotech Posted - 2 weeks ago

$IOVA trades at the lowest FY28 revenue multiple of all 11 comm'l-stage oncology focused bios w/market caps btwn $1 & $7.5B. At Stifel (11/19/24) IOVA CEO said IOVA has pathway to profitability "without the need for significant capital" that, common sense suggests, could come from working capital facilities v. equity/term debt. Also, EGFR wild-type potential is compelling with 6X more prevalence than 2L adv. melanoma. Frontline melanoma is also compelling opportunity w/30% CRR (long durations essentially a cure?). Investors worried about TIL cost should read: https://dailynews.ascopubs.org/do/pd-1-resistance-melanoma-if-avoidable $SWTX trades at the 3rd lowest multiple in this peer group even after recent surge (2/28/25 PDUFA is pot'l inflection point). M&A exit near? $MRUS approval yesterday adds new peer & pot'l volatility at 6.3X FY28 estimates (but maybe not too). $DAWN presented yesterday @ Piper Sandler. DAWN sees no near-term competitive threat. This is for info purposes only. This is not investment advice. $BPMC

User Image Dr_Van_Nostrend Posted - 2 weeks ago

$DAWN And that folks, is how you load a low float bio. Take notes... you buy 2M shares when nobody is looking at short 100K shares and close it flat, then do it again and again.

User Image CrispDry Posted - 2 weeks ago

$DAWN damn. They got me. Down 4%

User Image DonCorleone77 Posted - 2 weeks ago

$DAWN Attached is page 1 of a Piper Sandler analyst report on DAWN from yesterday entitled: "Live@PSC: Continued Confidence In Ojemda Trajectory, DAY301 External Validation" Piper has an 'Overweight' rating on DAWN with a $40 price target. Piper's "Conclusion' statement is as follows: "We hosted a Fireside Chat with DAWN management at the 36th Annual Piper Sandler Healthcare Conference earlier today. Our conversation centered around the ongoing commercialization of Omjeda in pLGG, its confidence around the durability of new patient starts, the opportunity to become standard of care 2L therapy, as well as the opportunity for re-treatment and expectations to provide guidance around FIREFLY-2 timelines in 2025. It also noted the external validation of its PTK7 ADC DAY301 via LLY's recently disclosed PTK7 ADC given very similar linker/payload design features. Additional details from our discussion follow below."

User Image CrispDry Posted - 2 weeks ago

$DAWN hopefully can rally the pop here to make up for my disastrous INTC trade

User Image Rollercoaster22 Posted - 2 weeks ago

$DAWN Someone hyst bought 2,16 m. shares at $13,80. 😱

User Image Smatty Posted - 2 weeks ago

$DAWN someone just bought 2M shares...

Analyst Ratings
JP Morgan Overweight Aug 6, 24
HC Wainwright & Co. Buy Aug 1, 24
B of A Securities Buy Aug 1, 24
Needham Buy Jul 31, 24
Needham Buy Jul 30, 24
HC Wainwright & Co. Buy Jul 26, 24
Piper Sandler Overweight Jul 8, 24
HC Wainwright & Co. Buy Jun 20, 24
Needham Buy Jun 19, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Nov 15 Sell 11.69 956 11,176 270,170 11/17/23
Dubow Adam General Counsel General Counsel Nov 15 Sell 11.69 5,313 62,109 11,428 11/17/23
Blackman Samuel C. Head of Research and.. Head of Research and Developme Nov 15 Sell 11.69 709 8,288 1,238,234 11/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Nov 15 Sell 11.69 3,107 36,321 709,429 11/17/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 15 Sell 13.86 922 12,779 267,501 08/17/23
Blackman Samuel C. Head of Research and.. Head of Research and Developme Aug 15 Sell 13.86 668 9,258 1,236,319 08/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 15 Sell 13.86 2,996 41,525 704,224 08/17/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer May 15 Sell 13.12 692 9,079 1,235,592 05/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer May 15 Sell 13.12 3,104 40,724 1,179,484 05/17/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Mar 10 Sell 18.0484 10,000 180,484 1,233,660 03/14/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Mar 07 Sell 20.0091 12,500 250,114 1,174,276 03/08/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Feb 17 Sell 20.0267 9,377 187,790 262,128 02/21/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Feb 15 Sell 19.57 674 13,190 1,243,660 02/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Feb 15 Sell 19.57 3,022 59,141 1,186,776 02/17/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Feb 10 Sell 20.0659 10,000 200,659 1,241,710 02/13/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jan 20 Sell 22.7523 10,000 227,523 268,810 01/23/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Jan 10 Sell 22.98 10,000 229,800 1,250,148 01/11/23
Grant Julie Papanek Director Director Jan 03 Sell 20.83 25,000 520,750 380,000 01/04/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Oct 03 Sell 20.0473 10,000 200,473 304,401 10/05/22
Grant Julie Papanek Director Director Oct 03 Sell 20.03 10,000 200,300 429,358 10/05/22
Grant Julie Papanek Director Director Sep 13 Sell 23.98 245,039 5,876,035 9,418,606 09/15/22
Canaan XI L.P. 10% Owner 10% Owner Sep 13 Sell 23.98 245,039 5,876,035 9,418,606 09/15/22
Grant Papanek Julie Director Director Sep 02 Sell 23.8215 5,000 119,108 439,358 09/15/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Sep 01 Sell 23.48 10,000 234,800 314,401 09/06/22
Grant Papanek Julie Director Director Sep 01 Sell 23.5 5,000 117,500 444,358 09/06/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Sep 01 Sell 23.47 10,000 234,700 1,289,338 09/06/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 23.47 12,500 293,375 1,240,375 09/06/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Aug 15 Option 0 3,561 1,300,279 08/17/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Aug 15 Sell 24.31 941 22,876 1,299,338 08/17/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 15 Option 0 10,686 1,256,878 08/17/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 15 Sell 24.31 4,003 97,313 1,252,875 08/17/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 15 Option 0 4,125 325,490 08/17/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 15 Sell 24.31 1,089 26,474 324,401 08/17/22
Grant Papanek Julie Director Director Aug 04 Sell 20 10,000 200,000 449,358 08/08/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 04 Sell 20.0541 10,000 200,541 321,365 08/05/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 04 Sell 20.0017 12,500 250,021 1,246,192 08/05/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Aug 01 Sell 16.881 10,000 168,810 1,296,718 08/03/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jul 18 Sell 20.00 2,500 50,000 331,365 07/20/22
Grant Papanek Julie Director Director Jul 18 Sell 20.0004 2,600 52,001 459,358 07/20/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Jul 18 Sell 20.0012 2,600 52,003 1,258,692 07/20/22
Grant Papanek Julie Director Director Jul 01 Sell 20 1,800 36,000 463,200 07/12/22
Grant Papanek Julie Director Director Jul 08 Sell 20.00 1,242 24,840 461,958 07/12/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jul 08 Sell 20.00 1,416 28,320 333,865 07/12/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Jul 08 Sell 20.00 1,795 35,900 1,261,292 07/12/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jul 01 Sell 20 2,279 45,580 335,281 07/06/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Jul 01 Sell 19.14 10,000 191,400 1,306,718 07/06/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Jul 01 Sell 20 2,603 52,060 1,263,087 07/06/22
Atlas Venture Opportunity Fund... 10% Owner 10% Owner Jun 17 Buy 15.00 766,667 11,500,005 766,667 06/22/22
Gladstone Michael Director Director Jun 17 Buy 15.00 766,667 11,500,005 766,667 06/22/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Jun 15 Sell 16.2631 50,000 813,155 1,316,718 06/17/22